Wednesday, March 4, 2015

Biotech Investing: Clinical Updates from Threshold (THLD) and Arqule (ARQL)

Both Threshold (THLD) and Arqule (ARQL) reported earnings in the last day and both provided updated guidance on the time of top line pivotal trial results of their pancreatic and liver cancer, respectively.

Threshold now expects results from its phase 3 pancreatic cancer trial in the first quarter of 2016.  Prior guidance was "sometime" in 2016 so now we are look at the front end of the year providing a closer trading catalyst.  The trial is being conducted by its partner Merck.

Arqule now expects results from its phase 3 liver cancer trail in the fourth quarter of 2015.  Previous guidance was the first quarter of 2016 but recruitment has been better than expected.

I have 6,000 shares of Threshold and don't plan to sell until we get closer to the pancreatic readout.  I may actually add to my position via selling naked puts.

I just sold my shares in Arqule earlier this week after it made a strong run these past few weeks after presentations at investor conferences.  I plan to get back in when/if it goes back below $1.70 per share.

Do your own research and good luck!

Biotech Investing: Hope you read and took action on my KaloBios (KBIO) on February 2nd!

I reported my position in KaloBios (KBIO) back on February 2nd when the shares were trading at $.39.  It seemed like such a good bargain that I picked up 60,000 shares.  Their book value was over $1 per share, the CEO "retired", and they still had a compound in phase 2 trials with results expected in the second quarter.  I don't know what the ultimate outcome will be but I sold my shares today at approximately $.92.  Not a bad hull for months work!

Keep looking for those bargains, do your research, and good luck!  

Monday, March 2, 2015

Biotech Investing: Merrimack (MACK) gets a shout out in Cramer's Lightning Round

Jim Cramer gave a positive vote of confidence during tonight's lightning round on Mad Money.  I've written a number of articles expressing my strong opinion (and large holding) of Merrimack.  It has a great pipeline and MM-398 should get approved for hard-to-treat pancreatic cancer later this year.

I currently hold 11,300 shares of Merrimack and no plans to buy our sell in the near future.



Merrimack Pharmaceuticals: "We like them! That was one of our spec pharma picks. We still continue to like it. I think it's in real good shape. You have a good one in Merrimack, we still like it."